Eli Lilly and Co.

J&J, Bayer fail to win U.S. OK for expanded Xarelto use

June 22, 2012
If approved for acute coronary syndrome, Xarelto would compete with Effient from Indianapolis-based Eli Lilly and Co and Brilinta from London-based AstraZeneca Plc.
More

Lilly resumes $3B stock buyback program, declares dividend

June 19, 2012
Associated Press
The local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
More

Largest Indiana public companies mostly fared well in 2011Restricted Content

June 16, 2012
Performance varied widely as industries ebbed, flowed.
More

Web domain requests include .Cialis, .Walmart

June 14, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. and other corporate heavyweights are applying for Web suffixes including .cialis, .walmart and .jpmorgan under a program to expand the number of Internet domain names beyond .com.
More

Lilly sinks $20M into Chinese firm for 'branded generic' drugs

June 12, 2012
J.K. Wall
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
More

Lilly chases Novo in insulin race

June 11, 2012
J.K. Wall
Eli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
More

Good cholesterol may not lower heart risk, study suggests

May 17, 2012
Bloomberg News
Raising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
More

U.S. losing drug-research jobs to other countries

May 17, 2012
Bloomberg News
Eli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore, Ireland and South Africa boost incentives.
More

Lilly unlikely to gain from Plavix patent loss, analyst says

May 17, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
More

Cancer tools help Roche with Alzheimer's drug

May 13, 2012
Bloomberg News
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
More

Roche scraps hoped-for cholesterol blockbuster

May 7, 2012
Associated Press
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing a similar drug.
More

Lilly: Forget Alzheimer's; think diabetes

May 7, 2012
J.K. Wall
For more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward the drugmaker’s diabetes portfolio.
More

Arrests made in $80M Lilly prescription drug heist

May 3, 2012
 IBJ Staff and Associated Press, Bloomberg News
Authorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney's office said Thursday.
More

Lilly letting U.S. researchers test failed compounds for new uses

May 3, 2012
Bloomberg News
More than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed at previously.
More

Lilly capitalizing on demand for testosterone drugs

May 2, 2012
Bloomberg News
The market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
More

Eli Lilly's Cialis faces faster-acting competition

April 30, 2012
 IBJ Staff and Bloomberg News
A Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and Co.'s Cialis or Pfizer Inc.’s Viagra,  has received U.S. regulatory approval.
More

Lilly tops analyst expectations despite shrinking profit, revenue

April 25, 2012
J.K. Wall
Lilly's quarterly sales and profit fell due to lost patent protection on Gemzar and Zyprexa. But sales of antidepressant Cymbalta, blood thinner Effient, animal health products and sales in China grew by 20 percent or more.
More

Poison pills remain as Lilly shareholder vote falls short

April 16, 2012
J.K. Wall
The proposal garnered support from the owners of 62 percent of Eli Lilly's outstanding shares. To pass, the proposal needed approval from the owners of 80 percent of Lilly’s shares.
More

Lilly CEO says cost-cutting won’t solve sales losses

April 13, 2012
Bloomberg News
Eli Lilly and Co., facing generic competition to two of its top drugs, needs to rely on new medicines rather than cost-cutting to overcome the revenue loss, CEO John Lechleiter said Thursday in Boston at the annual meeting of the Pharmaceutical Research and Manufacturers of America.
More

New Lilly drug has small sales potential

April 9, 2012
J.K. Wall
Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
More

Lilly wins FDA approval for Alzheimer's imaging agent

April 9, 2012
J.K. Wall
The agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
More

Lilly receives Europe's OK for new Byetta use

March 23, 2012
 IBJ Staff and Associated Press, Associated Press
European regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
More

Lilly to focus on cancer, diabetes in China, CEO says

March 20, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years, focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
More

PROXY CORNER: Eli Lilly and Co.Restricted Content

March 17, 2012
Indianapolis-based Eli Lilly and Co discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
More

Lilly to try again to remove poison-pill provisions

March 6, 2012
J.K. Wall
Eli Lilly and Co.'s board is once again recommending the removal of a provision that makes the company an almost impossible target for hostile takeovers. The same proposal has fallen slightly short at each of the past two annual shareholder meetings.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT